MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities

被引：81

作者：

Criniere, Emmanuelle

Kaloshi, Gentian

Laigle-Donadey, Florence

Lejeune, Julie

Auger, Nathalie

Benouaich-Amiel, Alexandra

Everhard, Sibille

Mokhtari, Karima

Polivka, Marc

Delattre, Jean-Yves

Hoang-Xuan, Khe

Thillet, Joelle

Sanson, Marc

机构：

[1] Grp Hosp Pitie Salpetriere, Serv Neurol Mazarin, F-75013 Paris, France

[2] Hop Lariboisiere, Serv Anatomopathol, F-75475 Paris, France

[3] Grp Hosp Pitie Salpetriere, Lab Neuropathol R, F-75634 Paris, France

[4] Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Serv Neurol Mazarin, F-75651 Paris 13, France

[5] Univ Paris 06, Fac Med, INSERM, U711, Paris, France

来源：

JOURNAL OF NEURO-ONCOLOGY | 2007年 / 83卷 / 02期

关键词：

glioblastoma; markers; prognosis; MGMT; chemotherapy;

D O I：

10.1007/s11060-006-9320-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MGMT promoter methylation, which has been correlated with the response to alkylating agents, was investigated in a retrospective series of 219 glioblastomas (GBMs) treated with various modalities. MGMT methylation had no impact on survival for the whole group, but showed a significant advantage (17.1 months vs. 13.1) for patients treated with RT+ adjuvant chemotherapy (relative risk of death (RR) = 0.53; P = 0.041), particularly when patients received CT during the course of RT (MS = 19.9 months vs. 12.5 months; RR = 0.227, P = 0.001). This suggests that the prognostic impact of MGMT methylation is dependent on therapeutic modalities and schedules. MGMT methylation was not correlated with the main molecular alterations, such as 10q loss and p53 expression.

引用

收藏

页码：173 / 179

页数：7

相关论文

共 27 条

[1]

Berggren P, 2003, CLIN CANCER RES, V9, P235

[2] Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas [J].

Blanc, JL ;

Wager, M ;

Guilhot, J ;

Kusy, S ;

Bataille, B ;

Chantereau, T ;

Lapierre, F ;

Larsen, CJ ;

Karayan-Tapon, L .

JOURNAL OF NEURO-ONCOLOGY, 2004, 68 (03) :275-283

[3] RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS [J].

CURRAN, WJ ;

SCOTT, CB ;

HORTON, J ;

NELSON, JS ;

WEINSTEIN, AS ;

FISCHBACH, AJ ;

CHANG, CH ;

ROTMAN, M ;

ASBELL, SO ;

KRISCH, RE ;

NELSON, DF .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) :704-710

[4] Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].

Esteller, M ;

Garcia-Foncillas, J ;

Andion, E ;

Goodman, SN ;

Hidalgo, OF ;

Vanaclocha, V ;

Baylin, SB ;

Herman, JG .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354

[5] Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes [J].

Grombacher, T ;

Mitra, S ;

Kaina, B .

CARCINOGENESIS, 1996, 17 (11) :2329-2336

[6] P53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents [J].

Grombacher, T ;

Eichhorn, U ;

Kaina, B .

ONCOGENE, 1998, 17 (07) :845-851

[7] Glioblastomas with an oligodendroglial component: A pathological and molecular study [J].

He, J ;

Mokhtari, K ;

Sanson, M ;

Marie, Y ;

Kujas, M ;

Huguet, S ;

Leuraud, P ;

Capelle, L ;

Delattre, JY ;

Poirier, J ;

Hoang-Xuan, K .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (09) :863-871

[8] MGMT gene silencing and benefit from temozolomide in glioblastoma [J].

Hegi, ME ;

Diserens, A ;

Gorlia, T ;

Hamou, M ;

de Tribolet, N ;

Weller, M ;

Kros, JM ;

Hainfellner, JA ;

Mason, W ;

Mariani, L ;

Bromberg, JEC ;

Hau, P ;

Mirimanoff, RO ;

Cairncross, JG ;

Janzer, RC ;

Stupp, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003

[9] O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells [J].

Hermisson, M ;

Klumpp, A ;

Wick, W ;

Wischhusen, J ;

Nagel, G ;

Roos, W ;

Kaina, B ;

Weller, M .

JOURNAL OF NEUROCHEMISTRY, 2006, 96 (03) :766-776

[10] Prognostic impact of molecular markers in a series of 220 primary glioblastomas [J].

Houillier, C ;

Lejeune, J ;

Benouaich-Amiel, A ;

Laigle-Donadey, F ;

Criniere, E ;

Mokhtari, K ;

Thillet, J ;

Delaffre, JY ;

Hoang-Xuan, K ;

Sanson, M .

CANCER, 2006, 106 (10) :2218-2223